ES2082201T3 - Uso de il-4 para mejorar la respuesta inmune a las pruebas de antigenos infecciosos. - Google Patents

Uso de il-4 para mejorar la respuesta inmune a las pruebas de antigenos infecciosos.

Info

Publication number
ES2082201T3
ES2082201T3 ES91906129T ES91906129T ES2082201T3 ES 2082201 T3 ES2082201 T3 ES 2082201T3 ES 91906129 T ES91906129 T ES 91906129T ES 91906129 T ES91906129 T ES 91906129T ES 2082201 T3 ES2082201 T3 ES 2082201T3
Authority
ES
Spain
Prior art keywords
agents
immune response
response
infectious
improve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91906129T
Other languages
English (en)
Inventor
Jerome Schwartz
Claude H Nash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2082201T3 publication Critical patent/ES2082201T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

SE PRESENTA EL USO DE IL-4 PARA LA FABRICACION DE UN MEDICAMENTO PARA INDUCIR UNA RESPUESTA INMUNE EFECTIVA A AGENTES INFECCIOSO CRONICOS ENDEMICOS EN UN MAMIFERO EXPUESTO A TALES AGENTES Y UNA COMPOSICION FARMACEUTICA PARA INDUCIR UNA RESPUESTA INMUNE EFECTIVA A LOS AGENTES INFECCIOSOS CRONICOS ENDEMICOS EN MAMIFEROS EXPUESTOS A TALES AGENTES, DICHAS COMPOSICIONES COMPRENDEN IL-4, PREFERIBLEMENTE IL-4 HUMANO RECOMBINANTE DEL "E. COLI" COMO INGREDIENTE ACTIVO, ASI MISMO SE PRESENTAN METODOS PARA INDUCIR UNA RESPUESTA INMUNE EFECTIVA A AGENTES INFECCIOSOS CRONICOS ENDEMICOS EN MAMIFEROS EXPUESTOS A TALES AGENTES MEDIANTE LA ADMINISTRACION A DICHOS MAMIFEROS DE UNA CANTIDAD EFECTIVA DE IL-4, PREFERIBLEMENTE IL-4 HUMANO RECOMBINANTE DERIVADO DEL "E. COLI".
ES91906129T 1990-03-21 1991-03-19 Uso de il-4 para mejorar la respuesta inmune a las pruebas de antigenos infecciosos. Expired - Lifetime ES2082201T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49683290A 1990-03-21 1990-03-21

Publications (1)

Publication Number Publication Date
ES2082201T3 true ES2082201T3 (es) 1996-03-16

Family

ID=23974340

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91906129T Expired - Lifetime ES2082201T3 (es) 1990-03-21 1991-03-19 Uso de il-4 para mejorar la respuesta inmune a las pruebas de antigenos infecciosos.

Country Status (19)

Country Link
EP (1) EP0521916B1 (es)
JP (1) JPH05505799A (es)
CN (1) CN1055116A (es)
AT (1) ATE133074T1 (es)
AU (1) AU656889B2 (es)
CA (1) CA2078676A1 (es)
DE (1) DE69116552T2 (es)
DK (1) DK0521916T3 (es)
ES (1) ES2082201T3 (es)
FI (1) FI924215L (es)
GR (1) GR3019018T3 (es)
HU (1) HUT63062A (es)
IE (1) IE72204B1 (es)
IL (1) IL97600A0 (es)
MY (1) MY108672A (es)
OA (1) OA09672A (es)
PT (1) PT97082B (es)
WO (1) WO1991014450A1 (es)
ZA (1) ZA912037B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100191223B1 (ko) * 1989-07-28 1999-06-15 둘락 노먼 씨. 인터루킨-4의 정제방법 및 이를 함유하는 약제학적 조성물
US5827670A (en) * 1990-08-02 1998-10-27 Fred Hutchinson Cancer Research Center Methods of isolating and detecting bone marrow stromal cells with VCAM-1-specific antibodies
US7449186B1 (en) 1990-08-02 2008-11-11 Fred Hutchinson Cancer Research Center Methods of blocking the interaction between stromal cells and hemopoietic cells with anti-VCAM-1 antibodies
AU9161591A (en) * 1990-12-19 1992-07-22 Schering Corporation Use of il-4 to enhance immune response to immunogens in vaccines
JPH0747545B2 (ja) * 1991-01-10 1995-05-24 シェリング・コーポレーション 創傷治癒及び修復の修復段階を促進し、かつ感染した創傷及び糖尿病哺乳類の創傷の治癒を促進するためのｉｌ−４の用途
GB9124347D0 (en) * 1991-11-15 1992-01-08 Isis Innovation Treatment of macrophages
CZ38095A3 (en) * 1992-08-19 1995-12-13 Schering Corp Pharmaceutical preparation for treating hiv infection, process of its preparation, il-4 and its use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL80678A (en) * 1985-11-19 1999-05-09 Schering Biotech Corp Human interleukin-4
EP0302429B1 (en) * 1987-08-03 1993-07-28 Tasuku Honjo Novel human interleukin 4, expression vectors for human interleukin 4 and transformants containing the same
JPH0236129A (ja) * 1988-07-22 1990-02-06 Ajinomoto Co Inc ワクチン効果増強剤
CA2045574A1 (en) * 1989-01-20 1990-07-21 John A. Hamilton Fibrinolysis

Also Published As

Publication number Publication date
IE72204B1 (en) 1997-04-09
ATE133074T1 (de) 1996-02-15
CN1055116A (zh) 1991-10-09
FI924215A7 (fi) 1992-09-21
OA09672A (en) 1993-05-15
DK0521916T3 (da) 1996-03-04
PT97082A (pt) 1991-11-29
AU7469091A (en) 1991-10-21
WO1991014450A1 (en) 1991-10-03
FI924215A0 (fi) 1992-09-21
MY108672A (en) 1996-10-31
AU656889B2 (en) 1995-02-23
IL97600A0 (en) 1992-06-21
DE69116552T2 (de) 1996-05-30
GR3019018T3 (en) 1996-05-31
EP0521916A1 (en) 1993-01-13
IE910921A1 (en) 1991-09-25
JPH05505799A (ja) 1993-08-26
DE69116552D1 (de) 1996-02-29
FI924215L (fi) 1992-09-21
HUT63062A (en) 1993-07-28
PT97082B (pt) 1998-07-31
EP0521916B1 (en) 1996-01-17
CA2078676A1 (en) 1991-09-22
ZA912037B (en) 1992-03-25

Similar Documents

Publication Publication Date Title
Dannenberg Jr Immunopathogenesis of pulmonary tuberculosis
SE8300623D0 (sv) Farmaceutisk komposition innehallande stabil mikrokristallin cis-platina(ii)-diammindiklorid (cisplatin)
BG60102B2 (bg) Метод за получаване на 5-флуор-2(((4-циклопропил- метокси-2-пиридинил)метил)тионил)-1н-бензимидазол
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
YU49698A (sh) Smeše koje sadrže tetrahidrolipstatin
SE8700499L (sv) Nya farmakologiskt aktiva foreningar
NO821832L (no) Fremgangsmaate for fremstilling av allergenholdige kapsler
MX171191B (es) Composiciones farmaceuticas de glipizida
ES2117015T3 (es) Composiciones que contienen sumatriptan.
ES2036593T3 (es) Composiciones que utilizan medicamentos antiinflamatorios no esteroidales encapsulados en liposomas.
DE69628163D1 (de) Nor-pregnane zur induzierung hypothalamischer effekte
ATE50499T1 (de) Pharmazeutische zusammensetzungen mit gehalt an flavanolignanen und phospholipiden als wirkstoffe.
ATE353009T1 (de) Prozess zur herstellung von pharmazeutischen zusammensetzungen zur verwendung mit weichgelatine formulierungen
DE69521693D1 (de) Taxanderivate enthaltende arzneizubereitungen
ES2141750T3 (es) Composicion que contiene a la vez una forma soluble y una forma insoluble de un inmunogeno.
ES2082201T3 (es) Uso de il-4 para mejorar la respuesta inmune a las pruebas de antigenos infecciosos.
FR2680172B1 (fr) Nouvelles piperazinylalcoyl-3 dihydro-2,3 4h-benzoxazine-1,3 ones-4 substituees, leur preparation et leur application en therapeutique.
ES2079851T3 (es) Uso de il-4 para mejorar la respuesta inmunitaria frente a inmunogenos en vacunas.
IT1204400B (it) Composizioni farmaceutiche contenente una calcitonina
ATE205397T1 (de) Natürliches menschliches alpha interferon enthaltende pharmazeutische zusammensetzungen
SE7708622L (sv) 2-bensyl-perhydroazepiner, sett for framstellning derav och lekemedel, innehallande dem
ES2064104T3 (es) Procedimiento de preparacion de composiciones farmaceuticas del tipo de liberacion prolongada destinadas a la administracion por via oral.
IT1243358B (it) Composizioni farmaceutiche per la somministrazione orale di irudina
KR920016104A (ko) 노인성 특발적 백내장 약제 제조를 위한 칼시토닌의 국소적용 용도 및 이의 약제학적 조성물
RU93043610A (ru) Фармацевтическая композиция для усиления первичной иммуно-реакции у млекопитающих, способ усиления первичной иммуно-реакции и применение интерлейкина-4 для усиления первичной иммуно-реакции у млекопитающих, набор лекарственных средств

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 521916

Country of ref document: ES